Fundraising FoxAvoro Capital Advisors — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Arie Belldegrun, M.D.(Executive Chairman and Co-Founder)inDavid Chang, M.D., Ph.D.(Co-Founder, Allogene)Christine Cassiano(Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer and one of the founders)inZachary Roberts, M.D., Ph.D.(President and Chief Executive Officer)ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Co-Founder and Director of Allogene)
Co-investorsForesite CapitalTPGVida VenturesGilead Sciences
Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development.
BiotechHealthtechBaltimore, US
James N. Campbell(President, Chief Scientific Officer)inKerrie L. Brady(Executive Officer)inGregg Beloff(Executive Officer)Jeffrey B. Kindler(Chief Executive Officer)inCharles Oh(Chief Medical Officer)inSmital Shah(Acting CBO)in
Co-investorsCatalio Capital Management, LPEFung CapitalNew Enterprise Associates (NEA)Quan Capital6 Dimensions CapitalExome Asset Management
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.